Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: Comparison of standardized quality depot versus aqueous extract

By Quercia Oliviero   Emiliani Francesca   Pecora Silvia   Burastero Samuele E.   Stefanini Giuseppe F.  

Allergy and Asthma Proceedings, Vol. 27, Iss. 2, 2006-03 ,pp. : 151-158

OceanSide Publications, Inc

Access to resources Recommend Favorite

Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells - An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta

By Bergh F.T.   Dayyani F.   Ziegler-Heitbrock L.  

Journal of Neuroimmunology, Vol. 146, Iss. 1, 2004-01 ,pp. : 176-188

Elsevier

Access to resources Recommend Favorite

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double‐blind placebo‐controlled study

By  

Immunity, Inflammation And Disease, Vol. 3, Iss. 2, 2015-06 ,pp. : 45-55

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pattern of sensitization to honeybee venom in beekeepers: A 5-year prospective study

By Kalogeromitros Dimitrios   Makris Michael   Gregoriou Stamatis   Papaioannou Dimitrios   Katoulis Alexandros   Stavrianeas Nicholaos G.  

Allergy and Asthma Proceedings, Vol. 27, Iss. 5, 2006-09 ,pp. : 383-387

OceanSide Publications, Inc

Access to resources Recommend Favorite

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

By Biehn Suzanne   Moore Dominic   Voorhees Peter   Garcia Reynaldo   Lehman Mary   Dees E.   Orlowski Robert  

Annals of Hematology, Vol. 86, Iss. 3, 2007-03 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite